CADTH
Toronto, April 27, 2020 – MORSE Consulting is pleased to release our April 2020 Update to the Canadian Reimbursement Trends and Timelines report – a comprehensive, credible and relevant source of market access intelligence. This 50+ PowerPoint report is aimed at assisting market access professionals plan for future launches and also serves as a valuable education tool for both internal and external stakeholders. What’s New in the April 2020 Update?…
pan-Canadian Pharmaceutical Alliance (pCPA): March 2020 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has launched a new website (https://www.pcpacanada.ca) with searchable data regarding brand name drug negotiations status and highlighting pCPA activity in the last four weeks. Highlights of the pCPA activity in March are: 5 products completed CADTH review, for a total of 16 files under consideration; 2 products initiated pCPA negotiations, for a total of 29…
pan-Canadian Pharmaceutical Alliance (pCPA): February 2020 Trends and Insights Due to the COVID-19 outbreak, the pCPA is implementing measures to work within the current reality while still attempting to meet its mandate. Consequently, some existing negotiations may be delayed or temporarily halted while the negotiating jurisdiction focuses on responding to the COVID-19 situation. The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the February 29, 2020 status of brand negotiations. Highlights…
Toronto, February 18, 2020 – MORSE Consulting is pleased to expand and strengthen our service offering with the addition of Anita Carrie and Roy Cairns. Affordability of effective and innovative medications within the current Canadian public funding model is becoming very challenging for the healthcare system. Increasing budgetary constraints coupled with complex treatments requiring consideration of different sources and levels of evidence are an issue for all stakeholders. To help…
pan-Canadian Pharmaceutical Alliance (pCPA): January 2020 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the January 31, 2020 status of brand negotiations. Highlights since the last update include: ● 2 products completed CADTH review, for a total of 9 files under consideration; ● 4 products initiated pCPA negotiations, for a total of 34 active negotiations; ● 2 negotiations completed for a total of 297 completed negotiations; ●…
pan-Canadian Pharmaceutical Alliance (pCPA): December 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the December 31, 2019 status of brand negotiations. Highlights since the last update include: 3 products completed CADTH review, for a total of 10 files under consideration; 0 products initiated pCPA negotiations, for a total of 32 active negotiations; 1 negotiation completed for a total of 295 completed negotiations; 1 negotiation closed, for…
pan-Canadian Pharmaceutical Alliance (pCPA): November 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the November 30, 2019 status of brand negotiations. Highlights since the last update include: 6 products completed CADTH review, for a total of 9 files under consideration; 4 products initiated pCPA negotiations, for a total of 34 active negotiations; 12 negotiations completed for a total of 294 completed negotiations; No negotiations closed, for…
Summary of CADTH Drug Portfolio Information Session Date: Monday, November 25, 2019 Time: 1:30 pm to 4:00 pm On November 25, 2019, CADTH hosted two information sessions in Toronto, Ontario for their Medical Device and Drug Portfolios. These annual sessions are an opportunity for stakeholders to get the latest information about priority initiatives and process changes. The summary below is separated into the following sections: Welcome and Strategic Overview…
The 2019 Real-World Evidence and Outcomes-Based Agreements Working Group research and outputs executive summary report is now available. The mission of the Real-World Evidence and Outcomes-Based Agreements Working Group is to advance the opportunity for the use of outcomes-based agreements in Canada.
pan-Canadian Pharmaceutical Alliance (pCPA): October 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the October 31, 2019 status of brand negotiations. Highlights since the last update include: 4 products completed CADTH review, for a total of 7 files under consideration; 2 products initiated pCPA negotiations, for a total of 42 active negotiations; 6 negotiations completed for a total of 282 completed negotiations; 2 negotiation closed, for…
pan-Canadian Pharmaceutical Alliance (pCPA): September 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the September 30, 2019 status of brand negotiations. Highlights since the last update include: 4 products completed CADTH review, for a total of 6 files under consideration; 8 products initiated pCPA negotiations, for a total of 48 active negotiations; 6 negotiations completed for a total of 276 completed negotiations; 1 negotiation closed, for…
Toronto, September 18, 2019 – MORSE Consulting is pleased to launch the Canadian Reimbursement Trends and Timelines report – a comprehensive, credible and relevant source of market access intelligence. The market access pathway in Canada is going through an unprecedented level of change and uncertainty. This 58-page PowerPoint report is aimed at not only helping market access professionals plan for future launches but can be a valuable education tool for…
pan-Canadian Pharmaceutical Alliance (pCPA): August 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the August 31, 2019 status of brand negotiations. Highlights since the last update include: 5 products completed CADTH review, for a total of 13 files under consideration; 8 products initiated pCPA negotiations, for a total of 47 active negotiations; 7 negotiations completed for a total of 270 completed negotiations; 1 negotiation closed, for…
Introduction MORSE Consulting is pleased to contribute its pCPA/public payer expertise with leading pricing and reimbursement experts and provide our respective views on how the new PMPRB regulations may impact the Canadian environment. These experts include: PMPRB: Joan McCormick, Principal Consultant - IQVIA HTA/Health Economics (HE): Sumeet Singh & Heather Cameron – Cornerstone Research Group Inc. Private Payers: Suzanne Lepage, Suzanne Lepage Consulting The purpose of this summary is two-fold:…
MORSE Consulting summary of CADTH update. On July 31, 2019 CADTH released its Pharmaceutical Reviews Update – Issue 9 and MORSE Consulting has prepared a brief summary of the important developments from this CADTH update. Consultations (Feedback to be provided by September 13, 2019) CADTH is inviting stakeholder comments and feedback on three proposals for the Pharmaceutical Review Programs. 1) Enhance the Transparency of CADTH’s Review Reports and Recommendations…
Contact Us
MORSE Consulting Inc.
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
CADTH - Info and details on - Page 4 of 6 - MORSE Consulting Inc.
